Where does the immune pressure go? New framework explains immunotherapy resistance
A new Molecular Cancer review proposes immune-pressure redistribution as a unifying framework explaining why patients resist PD-1/PD-L1 blockade and how ...
A new Molecular Cancer review proposes immune-pressure redistribution as a unifying framework explaining why patients resist PD-1/PD-L1 blockade and how ...
The Phase 3 EVOKE-03/KEYNOTE-D46 trial found that sacituzumab govitecan plus pembrolizumab did not significantly improve progression-free or overall survival compared ...
First clinical data from the Phase 1b/2 BNT324-01 trial show that the investigational combination of pumitamig and elfetabart drozuntecan achieved ...
A real-world study of 55 patients with advanced ROS1-rearranged non-small cell lung cancer shows that fusion subtype, PD-L1 expression and ...
A prospective imaging study shows that radium-223 significantly reduces PD-L1 expression and depletes immune cells in prostate cancer bone metastases, ...
Researchers are using PD-L1-targeted PET/CT imaging to directly visualise whether the immunotherapy drug atezolizumab saturates its target in tumours, offering ...
A new review in the Journal of Translational Medicine details how the RNA methyltransferase METTL3 drives tumor immune escape through ...
A full-thickness biopsy study of 40 dogs reveals that PD-L1 expression, rather than conventional histological features, is the strongest predictor ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine